Dr. Fréderic Rieux-Laucat
Gene therapy offers new therapeutic opportunities for immune deficiency associated with autoimmunity and inflammation such as Immunodysregulation-Polyendocrinopathy-Enteropathy X-linked (IPEX), X-linked chronic granulomatous disease (X-CGD) or for infectious diseases such as HIV. However, ongoing gene therapy trials of X-CGD patients, have shown that the patient’s inflammatory context is a significant barrier to the efficiency of hematopoietic stem cell transduction. Such an obstacle can be encountered in IPEX or HIV infection, which are accompanied by uncontrolled production of inflammatory cytokines. The developed project will measure femtogram concentrations of inflammatory cytokines, to monitor the inflammatory context and thus, optimize the efficiency of transduction in the treatment of these patients.
24 Boulevard du Montparnasse